![Dengue Vaccines Market (Category: Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, and Others; Product: CYD-TDV [Dengvaxia] and Others; Route of Administration: Subcutaneous and Others; and End User: Government Institutes, Specialty Clinics, Hospitals, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031「世界のデング熱ワクチン市場2021年-2031年：カテゴリー別（弱毒生ワクチン、キメラ生弱毒ワクチン、その他）、製品別、投与経路別、エンドユーザー別」（市場規模、市場予測）調査レポートです。](https://www.marketresearchcenter.net/images/market-size-forecast-data-61.GIF) | • レポートコード：MRC2106B045 • 出版社/出版日：Transparency Market Research / 2021年4月26日 • レポート形態：英文、PDF、200ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprise Licence | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界のデング熱ワクチン市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、カテゴリー別（弱毒生ワクチン、キメラ生弱毒ワクチン、その他）分析、製品別分析、投与経路別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを徹底分析したものです。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のデング熱ワクチン市場規模：カテゴリー別（弱毒生ワクチン、キメラ生弱毒ワクチン、その他） ・世界のデング熱ワクチン市場規模：製品別 ・世界のデング熱ワクチン市場規模：投与経路別 ・世界のデング熱ワクチン市場規模：エンドユーザー別 ・世界のデング熱ワクチン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Dengue Vaccines Market – Scope of the Report
TMR’s report on the global dengue vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global dengue vaccines market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dengue vaccines market from 2021 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the dengue vaccines market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the dengue vaccines market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global dengue vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dengue vaccines market.
The report delves into the competitive landscape of the global dengue vaccines market. Key players operating in the global dengue vaccines market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dengue vaccines market profiled in this report.
Key Questions Answered in Dengue Vaccines Market Report
What is the sales/revenue generated by dengue vaccines across all regions during the forecast period?
What are the opportunities in the global dengue vaccines market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which category is expected to generate the highest revenue globally in 2031? Which product is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Dengue Vaccines Market – Research Objectives and Research Approach
The comprehensive report on the global dengue vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global dengue vaccines market in terms of category, product, route of administration, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dengue vaccines market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dengue Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Category Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dengue Vaccines Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence
5.3. Patient Volume
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dengue Vaccines Market Analysis and Forecast, by Category
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Category, 2017–2031
6.3.1. Live Attenuated Vaccines
6.3.2. Chimeric Live Attenuated Vaccines
6.3.3. Others
6.4. Market Attractiveness Analysis, by Category
7. Global Dengue Vaccines Market Analysis and Forecasts, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017–2031
7.3.1. CYD-TDV (Dengvaxia)
7.3.2. Others
7.4. Market Attractiveness Analysis, by Product
8. Global Dengue Vaccines Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Subcutaneous
8.3.2. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Dengue Vaccines Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Government Institutes
9.3.3. Specialty Clinics
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Dengue Vaccines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Global Dengue Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Category, 2017–2031
11.2.1. Live Attenuated Vaccines
11.2.2. Chimeric Live Attenuated Vaccines
11.2.3. Others
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. CYD-TDV (Dengvaxia)
11.3.2. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Subcutaneous
11.4.2. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Government Institutes
11.5.3. Specialty Clinics
11.5.4. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Category
11.7.2. By Product
11.7.3. By Route of Administration
11.7.4. By End-user
11.7.5. By Country
12. Europe Global Dengue Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Category, 2017–2031
12.2.1. Live Attenuated Vaccines
12.2.2. Chimeric Live Attenuated Vaccines
12.2.3. Others
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. CYD-TDV (Dengvaxia)
12.3.2. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Subcutaneous
12.4.2. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Government Institutes
12.5.3. Specialty Clinics
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Category
12.7.2. By Product
12.7.3. By Route of Administration
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Global Dengue Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Category, 2017–2031
13.2.1. Live Attenuated Vaccines
13.2.2. Chimeric Live Attenuated Vaccines
13.2.3. Others
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. CYD-TDV (Dengvaxia)
13.3.2. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Subcutaneous
13.4.2. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Government Institutes
13.5.3. Specialty Clinics
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Category
13.7.2. By Product
13.7.3. By Route of Administration
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Global Dengue Vaccines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Category, 2017–2031
14.2.1. Live Attenuated Vaccines
14.2.2. Chimeric Live Attenuated Vaccines
14.2.3. Others
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. CYD-TDV (Dengvaxia)
14.3.2. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Subcutaneous
14.4.2. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Government Institutes
14.5.3. Specialty Clinics
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Category
14.7.2. By Product
14.7.3. By Route of Administration
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Global Dengue Vaccines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Category, 2017–2031
15.2.1. Live Attenuated Vaccines
15.2.2. Chimeric Live Attenuated Vaccines
15.2.3. Others
15.3. Market Value Forecast, by Product, 2017–2031
15.3.1. CYD-TDV (Dengvaxia)
15.3.2. Others
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Subcutaneous
15.4.2. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Government Institutes
15.5.3. Specialty Clinics
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Category
15.7.2. By Product
15.7.3. By Route of Administration
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sanofi Pasteur Limited
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Strategic Overview
16.2.2. Takeda Pharmaceutical Company Limited
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Strategic Overview
16.2.3. Merck Co. & Inc.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Strategic Overview
16.2.4. GlaxoSmithKline plc
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Strategic Overview
16.2.5. GeneOne Life Science
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Strategic Overview
16.2.6. Medigen Vaccine Biologics
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Strategic Overview
16.2.7. Panacea Biotec Limited
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Strategic Overview
16.2.8. Sun Pharmaceutical Industries Ltd.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Strategic Overview
16.2.9. Serum Institute of India Pvt. Ltd.
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Strategic Overview
16.2.10. Biological E
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Product Portfolio
16.2.10.3. SWOT Analysis
16.2.10.4. Strategic Overview
16.2.11. VabioTech
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Product Portfolio
16.2.11.3. SWOT Analysis
16.2.11.4. Strategic Overview